Adial Pharmaceuticals, Inc (ADIL) News
Filter ADIL News Items
ADIL News Results
|Loading, please wait...|
ADIL News Highlights
- ADIL's 30 day story count now stands at 2.
- Over the past 23 days, the trend for ADIL's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest ADIL News From Around the Web
Below are the latest news stories about ADIAL PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ADIL as an investment opportunity.
Adial to focus on late-stage clinical development for AD04 for alcohol use disorder; potential sale of Purnovate to new company formed by former Adial CEO and current Purnovate CEO, William Stilley Potential development/commercial milestone payments of up to $83 million on first three compounds plus equity stake and ongoing royalties CHARLOTTESVILLE, Va., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”) a clinical-stage biopharmaceuti
A share of Adial Pharmaceuticals Inc. (NASDAQ:ADIL) closed at $0.35 per share on Friday, up from $0.25 day before. While Adial Pharmaceuticals Inc. has overperformed by 37.29%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ADIL fell by -86.00%, with highs and lows ranging from $2.80 […]
Adial Pharmaceuticals, Inc. (ADIL) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
In a report released yesterday, Jason McCarthy from Maxim Group maintained a Hold rating on Adial Pharmaceuticals (ADIL - Research Report). The company's shares opened today at $0.29.McCarthy covers the Healthcare sector, focusing on stocks such as Immutep, Daré Bioscience, and Adial Pharmaceuticals. According to TipRanks, McCarthy has an average return of -38.1% and a 14.47% success rate on recommended stocks. The analyst consensus on Adial Pharmaceuticals is currently a Hold rating.See the top stocks recommended by analysts >>The company has a one-year high of $3.52 and a one-year low of $0.24. Currently, Adial Pharmaceuticals has an average volume of 166K.
Advancing submission of AD04 ONWARD™ phase 3 results to regulatory agencies Actively exploring potential partnership opportunities for AD04 and Purnovate compounds
Adial Pharmaceuticals, Inc: Adial Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
Advancing submission of AD04 ONWARD™ phase 3 results to regulatory agencies Actively exploring potential partnership opportunities for AD04 and Purnovate compounds Promoted Cary Claiborne to Presi…
Bet on these top-ranked stocks with rising P/E to realize outsized gains. Tap Eastside Distilling (EAST), Adial Pharmaceuticals (ADIL), The Buckle (BKE), Ruth's Hospitality Group (RUTH), Insight Enterprises (NSIT).
Maxim Group analyst Jason McCarthy maintained a Hold rating on Adial Pharmaceuticals (ADIL - Research Report) yesterday. The company's shares opened today at $0.42.According to TipRanks, McCarthy is an analyst with an average return of -44.0% and an 8.84% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Adial Pharmaceuticals, Atossa Therapeutics, and Capricor Therapeutics.Adial Pharmaceuticals has an analyst consensus of Moderate Buy.See Insiders’ Hot Stocks on TipRanks >> The company has a one-year high of $5.00 and a one-year low of $0.34. Currently, Adial Pharmaceuticals has an average volume of 737.3K.
Adial Pharmaceuticals Inc''s (NASDAQ: ADIL ) subsidiary, Purnovate Inc, achieved positive in vivo data for PNV-5030 as a potential treatment for chronic pain. The study was conducted in four groups of ten rats that underwent surgical injury of the sciatic nerve. At 30 minutes post-dose, PNV-5030 reduced pain by 43% compared to the control group, while acetaminophen (APAP) doses did not … Full story available on Benzinga.com
Adial Pharmaceuticals Announces Positive In Vivo Data for Purnovate’s PNV-5030 as a Potential Treatment for Chronic Pain
PNV-5030 significantly reduced pain compared to both placebo and acetaminophen PNV-5030 significantly reduced pain compared to both placebo and acetaminophen